Orally treated DM patients were more frequently women, whereas insulin-treated DM patients were younger.

An increased overall survival and CRC-specific survival in patients with CRC and metformin- treated DM has still not been substantially proven.

This review may help future researchers in identifying a right plant molecule to treat DM or to develop food formulations for DM management.

Several studies have shown a decreased risk of developing CRC in patients with metformin- treated DM, compared with patients with diabetes not treated with metformin.

The present study hypothesized that the high proportion of NETs observed in the cases of metformin- treated DM-II was unlikely to be a random event.